|
US4229447A
(en)
|
1979-06-04 |
1980-10-21 |
American Home Products Corporation |
Intraoral methods of using benzodiazepines
|
|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5116817A
(en)
|
1982-12-10 |
1992-05-26 |
Syntex (U.S.A.) Inc. |
LHRH preparations for intranasal administration
|
|
US4596795A
(en)
|
1984-04-25 |
1986-06-24 |
The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services |
Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
|
|
US5011692A
(en)
|
1985-12-28 |
1991-04-30 |
Sumitomo Pharmaceuticals Company, Limited |
Sustained pulsewise release pharmaceutical preparation
|
|
US4755386A
(en)
|
1986-01-22 |
1988-07-05 |
Schering Corporation |
Buccal formulation
|
|
US5739136A
(en)
|
1989-10-17 |
1998-04-14 |
Ellinwood, Jr.; Everett H. |
Intraoral dosing method of administering medicaments
|
|
US5017381A
(en)
|
1990-05-02 |
1991-05-21 |
Alza Corporation |
Multi-unit pulsatile delivery system
|
|
US5229135A
(en)
|
1991-11-22 |
1993-07-20 |
Prographarm Laboratories |
Sustained release diltiazem formulation
|
|
US5523302A
(en)
|
1993-11-24 |
1996-06-04 |
The Du Pont Merck Pharmaceutical Company |
Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
|
|
US20030198640A1
(en)
|
1994-11-07 |
2003-10-23 |
Human Genome Sciences, Inc. |
Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
|
|
US5837284A
(en)
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
|
US5858401A
(en)
|
1996-01-22 |
1999-01-12 |
Sidmak Laboratories, Inc. |
Pharmaceutical composition for cyclosporines
|
|
US6458373B1
(en)
|
1997-01-07 |
2002-10-01 |
Sonus Pharmaceuticals, Inc. |
Emulsion vehicle for poorly soluble drugs
|
|
US5840329A
(en)
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
US7531310B2
(en)
|
2000-11-17 |
2009-05-12 |
Bristol-Myers Squibb Company |
Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11
|
|
JP2005504510A
(ja)
|
2000-11-17 |
2005-02-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
心臓で高度に発現される新規なヒトｇタンパク質共役レセプター、ｈｇｐｒｂｍｙ１１およびその変異体
|
|
US20030224400A1
(en)
|
2000-11-17 |
2003-12-04 |
Barber Lauren E. |
Novel human G-protein coupled receptor, HGPRBMY11, and variants thereof
|
|
SE0004928D0
(sv)
|
2000-12-29 |
2000-12-29 |
Apbiotech Ab |
A method for the manufacturing of porous material
|
|
WO2002059264A2
(en)
|
2000-12-29 |
2002-08-01 |
Bio-Technology General Corp. |
Specific human antibodies for selective cancer therapy
|
|
BRPI0116728B1
(pt)
|
2001-01-05 |
2018-10-30 |
Pfizer Inc. |
anticorpos para receptor de fator de crescimento i semelhante à insulina
|
|
US6960563B2
(en)
|
2001-08-31 |
2005-11-01 |
Morton Grove Pharmaceuticals, Inc. |
Spontaneous emulsions containing cyclosporine
|
|
US11268149B2
(en)
|
2004-12-08 |
2022-03-08 |
Cedars-Sinai Medical Center |
Diagnosis and treatment of inflammatory bowel disease
|
|
US10544459B2
(en)
|
2004-12-08 |
2020-01-28 |
Cedars-Sinai Medical Center |
Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
|
|
US20090317388A1
(en)
|
2005-05-25 |
2009-12-24 |
Linda Burkly |
Tl1a in treatment of disease
|
|
ATE518011T1
(de)
|
2006-04-07 |
2011-08-15 |
Hitachi Chemical Co Ltd |
Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
|
|
US20080085524A1
(en)
|
2006-08-15 |
2008-04-10 |
Prometheus Laboratories Inc. |
Methods for diagnosing irritable bowel syndrome
|
|
WO2008106451A2
(en)
|
2007-02-26 |
2008-09-04 |
Cedars-Sinai Medical Center |
Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
|
|
WO2008107389A1
(en)
|
2007-03-02 |
2008-09-12 |
Universite De Liege |
A method for determining the genotype at the crohn's disease locus
|
|
US9305137B1
(en)
|
2007-05-18 |
2016-04-05 |
Cedars-Sinai Medical Center |
Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
|
|
US20150376707A1
(en)
|
2007-05-18 |
2015-12-31 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating inflammatory bowel disease
|
|
US20100240043A1
(en)
|
2007-10-19 |
2010-09-23 |
Cedars-Sinai Medical Center |
Methods of using genetic variants to diagnose and predict inflammatory bowel disease
|
|
SI2257643T1
(sl)
|
2008-02-19 |
2018-12-31 |
The Children's Hospital Of Philadelphia |
Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni
|
|
CN102171365B
(zh)
|
2008-08-25 |
2014-01-29 |
森托科尔奥索生物科技公司 |
用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物
|
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
|
US9580752B2
(en)
|
2008-12-24 |
2017-02-28 |
Cedars-Sinai Medical Center |
Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
|
|
CA2758531C
(en)
|
2009-04-14 |
2018-11-13 |
Derren Barken |
Inflammatory bowel disease prognostics
|
|
CN102639710A
(zh)
|
2009-07-20 |
2012-08-15 |
基因泰克公司 |
克罗恩病的基因表达标记
|
|
US8301232B2
(en)
|
2010-06-08 |
2012-10-30 |
Alivecor, Inc. |
Wireless, ultrasonic personal health monitoring system
|
|
JP2013540995A
(ja)
|
2010-08-18 |
2013-11-07 |
カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． |
疾患に対する循環バイオマーカー
|
|
US8766034B2
(en)
|
2010-09-22 |
2014-07-01 |
Cedars-Sinai Medical Center |
TL1A model of inflammation fibrosis and autoimmunity
|
|
NZ609363A
(en)
|
2010-10-18 |
2015-04-24 |
Nestec Sa |
Methods for determining anti-drug antibody isotypes
|
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
US9902996B2
(en)
|
2011-02-11 |
2018-02-27 |
Cedars-Sinai Medical Center |
Methods of predicting the need for surgery in crohn's disease
|
|
JP2014517279A
(ja)
|
2011-05-10 |
2014-07-17 |
ネステク ソシエテ アノニム |
個別治療管理のための疾患活動性プロファイリングの方法
|
|
KR102035877B1
(ko)
|
2011-11-14 |
2019-10-23 |
알파시그마 에스.피.에이. |
우울증이 있는 대상체를 위한 치료 양생법 선택을 위한 검정법 및 치료 방법
|
|
EA201591153A1
(ru)
|
2013-01-02 |
2016-01-29 |
Гленмарк Фармасьютикалс С.А. |
Антитела, связывающиеся с tl1a, и их применение
|
|
KR102343212B1
(ko)
|
2013-03-27 |
2021-12-23 |
세다르스-신나이 메디칼 센터 |
Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
|
|
WO2014186750A2
(en)
|
2013-05-17 |
2014-11-20 |
Cedars-Sinai Medical Center |
Variants of tnfsf15 and dcr3 associated with crohn's disease
|
|
SG11201509371XA
(en)
|
2013-05-24 |
2015-12-30 |
Nestec Sa |
Pathway specific markers for diagnosing irritable bowel syndrome
|
|
WO2015010108A1
(en)
|
2013-07-19 |
2015-01-22 |
Cedars-Sinai Medical Center |
Signature of tl1a (tnfsf15) signaling pathway
|
|
US10349888B2
(en)
|
2013-10-08 |
2019-07-16 |
Carlos Federico Muniz |
Wearable electroencephalography device and methods of use thereof
|
|
MX388027B
(es)
*
|
2013-11-13 |
2025-03-19 |
Pfizer |
Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos.
|
|
WO2022187196A1
(en)
|
2021-03-02 |
2022-09-09 |
Dermtech, Inc. |
Predicting therapeutic response
|
|
WO2015136446A1
(en)
|
2014-03-11 |
2015-09-17 |
Nestec S.A. |
Methods for selecting antidepressant drug therapy to treat depression
|
|
KR20220065091A
(ko)
|
2014-03-27 |
2022-05-19 |
제넨테크, 인크. |
염증성 장 질환의 진단 및 치료 방법
|
|
US10261098B2
(en)
|
2014-08-18 |
2019-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for diagnosis and management of neuro-immunological diseases
|
|
WO2016040879A1
(en)
|
2014-09-12 |
2016-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Physical examination method and apparatus
|
|
MX2017004742A
(es)
|
2014-10-20 |
2017-07-20 |
Nestec Sa |
Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
|
|
US10477354B2
(en)
|
2015-02-20 |
2019-11-12 |
Mc10, Inc. |
Automated detection and configuration of wearable devices based on on-body status, location, and/or orientation
|
|
HK1257443A1
(zh)
|
2015-08-21 |
2019-10-18 |
The Children's Hospital Of Philadelphia |
治疗具有dcr3或dcr3网络基因中的遗传变异的患者的自身免疫病症的方法
|
|
TWI703158B
(zh)
|
2015-09-18 |
2020-09-01 |
美商希佛隆公司 |
特異性結合tl1a之抗體
|
|
US11266730B2
(en)
|
2015-09-29 |
2022-03-08 |
The General Hospital Corporation |
Methods of treating and diagnosing disease using biomarkers for BCG therapy
|
|
CR20180365A
(es)
*
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
US10732092B2
(en)
|
2015-12-22 |
2020-08-04 |
University Of Maryland, College Park |
Analysis of single cell mechanical phenotyping for metastatic detection
|
|
US11186872B2
(en)
|
2016-03-17 |
2021-11-30 |
Cedars-Sinai Medical Center |
Methods of diagnosing inflammatory bowel disease through RNASET2
|
|
WO2017189846A1
(en)
|
2016-04-27 |
2017-11-02 |
Thaddeus Stappenbeck |
Methods for prognosing crohn's disease comprising human defensin 5 (hd5)
|
|
KR102481305B1
(ko)
|
2016-05-20 |
2022-12-26 |
세다르스-신나이 메디칼 센터 |
유전자에 기반한 염증성 장 질환의 진단
|
|
US10458996B1
(en)
|
2016-05-20 |
2019-10-29 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for determining clinical response to TNF-alpha and/or JAK inhibitors in subjects with inflammatory diseases
|
|
MY191324A
(en)
|
2016-10-26 |
2022-06-15 |
Cedars Sinai Medical Center |
Neutralizing anti-tl1a monoclonal antibodies
|
|
CN110446508A
(zh)
|
2016-12-29 |
2019-11-12 |
泰普治疗公司 |
用于治疗医疗植入物部位的方法和系统
|
|
US20190070166A1
(en)
|
2017-09-02 |
2019-03-07 |
Richard Postrel |
Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
|
|
US10961581B2
(en)
|
2017-03-22 |
2021-03-30 |
Board Of Regents, The University Of Texas System |
Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932)
|
|
US10635787B2
(en)
|
2017-04-19 |
2020-04-28 |
International Business Machines Corporation |
Analysis of output files
|
|
US10626180B2
(en)
|
2017-04-20 |
2020-04-21 |
Cedars-Sinai Medical Center |
Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease
|
|
EP3654993A4
(en)
|
2017-07-17 |
2021-08-25 |
The Broad Institute, Inc. |
CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
|
|
US20220112625A1
(en)
|
2017-09-02 |
2022-04-14 |
Richard Postrel |
Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses
|
|
EP3695229A1
(en)
|
2017-10-10 |
2020-08-19 |
Prometheus Biosciences, Inc. |
Methods for monitoring vedolizumab treatment
|
|
WO2019079647A2
(en)
|
2017-10-18 |
2019-04-25 |
Wuxi Nextcode Genomics Usa, Inc. |
IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES
|
|
US12599656B2
(en)
|
2018-03-12 |
2026-04-14 |
Stemcell Technologies Canada Inc. |
Methods for treating HPV-associated diseases
|
|
EP3778328B1
(en)
|
2018-03-27 |
2023-05-17 |
Nissan Motor Co., Ltd. |
Method and device for controlling automatic driving vehicle
|
|
CA3097874A1
(en)
|
2018-04-24 |
2019-10-31 |
Cedars-Sinai Medical Center |
Methods and systems for characterizing severe crohn's disease
|
|
JP7332627B2
(ja)
|
2018-04-25 |
2023-08-23 |
プロメテウス バイオサイエンシーズ，インク． |
最適化された抗ｔｌ１ａ抗体
|
|
TW202014217A
(zh)
|
2018-04-27 |
2020-04-16 |
美國錫安山醫學中心 |
標靶gpr35以治療發炎性腸病症的組合物及方法
|
|
ES2962715T3
(es)
|
2018-04-30 |
2024-03-20 |
Cedars Sinai Medical Center |
Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
|
|
CA3105464A1
(en)
|
2018-07-06 |
2020-01-09 |
Cedars-Sinai Medical Center |
Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
|
|
WO2020081186A1
(en)
|
2018-10-15 |
2020-04-23 |
Cedars-Sinai Medical Center |
Methods of treating and diagnosing inflammatory bowel disease
|
|
WO2020082090A1
(en)
|
2018-10-19 |
2020-04-23 |
The Regents Of The University Of Michigan |
Method for monitoring autoimmune disease
|
|
WO2020112890A1
(en)
|
2018-11-29 |
2020-06-04 |
Cedars-Sinai Medical Center |
Rnaset2 compositions and methods of treatment therewith
|
|
CA3121167A1
(en)
|
2018-11-29 |
2020-06-04 |
Cedars-Sinai Medical Center |
Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
|
|
CA3124970A1
(en)
|
2018-12-28 |
2020-07-02 |
Cedars-Sinai Medical Center |
Methods of treating inflammatory bowel diseases that target ripk2
|
|
TWI845600B
(zh)
|
2019-01-24 |
2024-06-21 |
美商普羅米修斯生物科學股份有限公司 |
Gpr35調節劑
|
|
KR20210130168A
(ko)
|
2019-02-08 |
2021-10-29 |
세다르스-신나이 메디칼 센터 |
Il18r1을 표적화하는 염증성 질환의 치료를 위한 방법, 시스템 및 키트
|
|
WO2020163713A1
(en)
|
2019-02-08 |
2020-08-13 |
Cedars-Sinai Medical Center |
Methods, systems, and kits for treating inflammatory disease targeting skap2
|
|
CA3131701A1
(en)
|
2019-02-28 |
2020-09-03 |
Sqz Biotechnologies Company |
Delivery of biomolecules to pbmcs to modify an immune response
|
|
JP2022533956A
(ja)
|
2019-05-14 |
2022-07-27 |
プロメテウス バイオサイエンシーズ，インク． |
Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
|
|
WO2020242976A1
(en)
|
2019-05-24 |
2020-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for diagnosis of polygenic diseases and phenotypes from genetic variation
|
|
US20210018490A1
(en)
|
2019-07-19 |
2021-01-21 |
The Regents Of The University Of Michigan |
Compositions and methods for individualized characterization of non-ige mediated food allergies
|
|
WO2021081365A1
(en)
|
2019-10-24 |
2021-04-29 |
Prometheus Biosciences, Inc. |
Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
|
|
KR20220103721A
(ko)
|
2019-10-24 |
2022-07-22 |
프로메테우스 바이오사이언시즈, 인크. |
Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
|
|
CA3162905A1
(en)
|
2019-11-27 |
2021-06-03 |
Cedars-Sinai Medical Center |
Predicting extraintestinal manifestations of inflammatory bowel disease
|
|
EP4162067A4
(en)
|
2020-06-03 |
2024-07-10 |
Cedars-Sinai Medical Center |
METHODS AND SYSTEMS FOR MEASURING THE RECURRENCE OF POSTOPERATIVE DISEASES
|
|
EP4162076A4
(en)
|
2020-06-03 |
2024-10-02 |
Cedars-Sinai Medical Center |
TREATMENTS FOR A SUBPOPULATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
|
|
CN116322762A
(zh)
|
2020-06-26 |
2023-06-23 |
辉瑞公司 |
用tl1a抗体治疗炎症性肠病的方法
|
|
WO2022087313A1
(en)
|
2020-10-22 |
2022-04-28 |
Progenity, Inc. |
Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
|
|
US20240018592A1
(en)
|
2020-10-26 |
2024-01-18 |
Technion Research & Development Foundation Limited |
Methods of assessing the therapeutic activity of agents for the treatment of immune disorders
|
|
CA3197828A1
(en)
|
2020-11-13 |
2022-05-19 |
Laurens Kruidenier |
Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
|
|
EP4256086A4
(en)
|
2020-12-01 |
2025-01-15 |
Cedars-Sinai Medical Center |
METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES
|
|
EP4263585A4
(en)
|
2020-12-21 |
2024-11-27 |
Cedars-Sinai Medical Center |
THERAPEUTIC COMPOSITIONS OF TL1A AND METHODS OF TREATMENT USING THEM
|
|
CA3207818A1
(en)
|
2021-02-18 |
2022-08-25 |
Allison LUO |
Anti-tl1a antibody compositions and methods of treatment in the lung
|
|
AU2022223420A1
(en)
|
2021-02-18 |
2023-09-21 |
Cedars-Sinai Medical Center |
Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
|
|
MX2023010694A
(es)
|
2021-03-12 |
2023-11-23 |
Janssen Biotech Inc |
Métodos para predecir la respuesta al tratamiento en la colitis ulcerosa.
|
|
WO2022232253A1
(en)
|
2021-04-28 |
2022-11-03 |
Cedars-Sinai Medical Center |
Patient selection methods and kits for therapies targeting tl1a
|